Dietary supplementation with Lovaza and krill oil shortens the life span of long-lived F1 mice
Open Access
- 10 May 2014
- journal article
- research article
- Published by Springer Nature in AGE
- Vol. 36 (3) , 1345-1352
Abstract
Marine oils rich in ω-3 polyunsaturated fatty acids have been recommended as a preventive treatment for patients at risk for cardiovascular diseases. These oils also are the third most consumed dietary supplement in the USA. However, evidence for their health benefits is equivocal. We tested the daily, isocaloric administration of krill oil (1.17 g oil/kg diet) and Lovaza (Omacor; 4.40 g/kg diet), a pharmaceutical grade fish oil, beginning at 12 months of age, on the life span and mortality-related pathologies of long-lived, male, B6C3F1 mice. The oils were incorporated into the chemically defined American Institute of Nutrition (AIN)-93 M diet. An equivalent volume of soybean oil was removed. Krill oil was 3 % and Lovaza 11 % of the oil in the diets. When their effects were analyzed together, the marine oils significantly shortened life span by 6.6 % (P = 0.0321; log-rank test) relative to controls. Individually, Lovaza and krill oil non-significantly shortened median life span by 9.8 and 4.7 %, respectively. Lovaza increased the number of enlarged seminal vesicles (7.1-fold). Lovaza and krill oil significantly increased lung tumors (4.1- and 8.2-fold) and hemorrhagic diathesis (3.9- and 3.1-fold). Analysis of serum from treated mice found that Lovaza slightly increased blood urea nitrogen, while krill oil modestly increased bilirubin, triglycerides, and blood glucose levels. Taken together, the results do not support the idea that the consumption of isolated ω-3 fatty acid-rich oils will increase the life span or health of initially healthy individuals.Keywords
This publication has 38 references indexed in Scilit:
- Minimum Size Survival Analysis Sampling Plans for Comparing Multiple Treatment Groups to a Single Control GroupCommunications in Statistics - Theory and Methods, 2014
- Omacor and Omega-3 Fatty Acids for Treatment of Coronary Artery Disease and the Pleiotropic EffectsAmerican Journal of Therapeutics, 2014
- Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT TrialJNCI: Journal of the National Cancer Institute, 2013
- Plasma phospholipid fatty acids, dietary fatty acids and prostate cancer riskInternational Journal of Cancer, 2013
- Marine omega-3 fatty acids and coronary heart diseaseCurrent Opinion in Cardiology, 2012
- Are drugmakers fishing for a market with prescription omega-3s?Nature Medicine, 2012
- n–3 Fatty Acids in Cardiovascular DiseaseNew England Journal of Medicine, 2011
- n–3 Fatty Acids and Cardiovascular Events after Myocardial InfarctionNew England Journal of Medicine, 2010
- Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic miceExperimental Gerontology, 2005
- Temporal linkage between the phenotypic and genomic responses to caloric restrictionProceedings of the National Academy of Sciences, 2004